On April 18, 2025, AKESO (9926.HK) announced that its independently developed Adalimumab (Iroquois monoclonal antibody, IL-12/IL-23 "dual-target" monoclonal antibody) has been approved for marketing by the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis in adult patients. Iroquois monoclonal antibody is the first and only approved IL-12/IL-23 "dual-target" monoclonal antibody new drug, and it is AKESO's first approved new drug in the field of autoimmune diseases, as well as the company's second approved non-oncology new drug following Inusi monoclonal antibody.